GxP inspectors do not audit the procedure manual. They audit whether the process described in it is the process actually followed, batch after batch, site after site. IGX360 Insights gives pharmaceutical and biotechnology organisations a live, evidenced view of that alignment, so an EMA or national competent authority inspection is not the first time the gap between documented and actual practice gets found.
The documented process is an opinion rather than an operational truth. The underlying weakness is the absence of a governed, connected and queryable representation of the operating model.
Versions conflict, ownership becomes stale and people stop trusting central content. The underlying weakness is the absence of a governed, connected and queryable representation of the operating model.
Compliance gaps remain invisible until assurance activity begins. The underlying weakness is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
The model becomes shelfware and execution develops uncontrolled workarounds. The underlying weakness is the absence of a controlled connection between process design, executable work, decision rights and runtime evidence.
The organisation can see that something happened but cannot reliably learn why. The underlying weakness is the absence of an operating model that defines purpose, authority, constraints, evidence, escalation and revocation for human, agentic and hybrid actors.
The organisation cannot see which processes create each risk, which controls operate within them or where coverage is absent. The underlying weakness is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
Affected processes, systems, controls, roles and suppliers are identified manually and inconsistently. The underlying weakness is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
Procedures, roles, systems, controls and inspection evidence drift across the medicinal-product lifecycle. The underlying weakness is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
Governance does not reliably change tasks, decision thresholds, approvals, escalation or evidence capture. The underlying weakness is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
Mitigations, competence, occurrence reporting and assurance are not consistently embedded in everyday workflow. The underlying weakness is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
No results found.
Search is temporarily unavailable. Please try again shortly.
Start typing to search the whole site.
Required for the site to function. Always on.
Google Analytics, via Google Tag Manager. Helps us see which pages are useful.